Simon Cai
Senior Associate
Get their honest, personalized take on your startup.
Sign in to pitch Simon →At a glance
- Full Name
- Simon Cai
- Title
- Principal (previously Vice President; joined as an associate/senior associate) — Investment Team
- Firm
- Penfund
- Firm Type
- Private capital / direct lending firm — provider of senior and junior (mezzanine) capital to middle-market companies (not an angel investor)
- Investment Stage
- Established, cash-generative middle-market companies (buyouts, recapitalizations, acquisitions, shareholder liquidity, growth) — not seed/startup stage
- Check Size
- Up to C$225 million per transaction; can hold up to ~C$300 million (or USD equivalent) hold-to-maturity
- Target Company Profile
- Middle-market businesses typically generating at least ~US$20 million of annual EBITDA; asset-light companies that convert 80–90% of EBITDA to free cash flow, often selling non-discretionary, non-deferrable consumable goods/services
- Sector Focus
- Sector-agnostic, with activity across consumer services, business services, healthcare, and financial/industrial services
- Geographic Focus
- North America (Canada and the United States)
- Location
- Toronto, Ontario, Canada (333 Bay Street, Suite 610)
Background
Simon Cai is a member of the investment team at Penfund, a Toronto-based private capital firm founded in 1979 that provides senior and junior capital to middle-market companies across North America. He joined Penfund in 2018 and has risen through the firm's investment ranks — he was promoted to Vice President effective April 1, 2022, and is now listed as a Principal at the firm. His work centers on originating, underwriting, and managing Penfund's debt and structured-capital investments, which are deployed through vehicles such as Penfund Prime (senior direct lending) and the Penfund Capital Fund series (junior/mezzanine capital).
Before Penfund, Cai worked in the Real Estate Investment Banking Group at BMO Capital Markets and in the Infrastructure Advisory Group at Deloitte LLP, giving him a background spanning M&A/financing advisory and structured infrastructure finance. He holds a Bachelor of Commerce and a Bachelor of Science in Mathematics, both from Queen's University, and is a CFA charterholder.
It is worth flagging that the original stub data ("Angel Investors / Seed Round / Senior Associate") does not match verifiable sources. Penfund is a middle-market private credit and junior-capital firm — not an angel or seed-stage investor — and Cai's current title is Principal. Founders seeking pre-seed or seed equity are not Penfund's target; the firm finances mature, cash-flow-positive companies with meaningful EBITDA.
Penfund has deployed more than C$4.3 billion across roughly 75 investments since 2000, with assets and capital under management exceeding C$3.5 billion sourced from pension funds, insurance companies, banks, family offices, and high-net-worth investors in Canada, the U.S., the Middle East, and Europe.
Investment Thesis & Focus
- What Penfund funds: Senior and junior (mezzanine/structured) debt and related capital for middle-market companies to support buyouts, recapitalizations, acquisitions, shareholder liquidity, and growth — deployed via Penfund Prime (senior) and Penfund Capital Fund VII (junior).
- Size of company: Typically businesses generating at least ~US$20 million of annual EBITDA — i.e., established mid-market firms, not early-stage startups.
- Check size: Large, concentrated positions — commitments up to C$225 million, and hold capacity up to ~C$300 million per transaction as a hold-to-maturity lender.
- Company profile they favor: Asset-light businesses that convert 80–90% of EBITDA into free cash flow, frequently selling inexpensive, non-discretionary, non-deferrable consumable goods and services (resilient demand).
- Sector stance: No fixed industry preference; the firm evaluates opportunities broadly across consumer, business services, healthcare, industrial, and financial-services end markets.
- Style: Relationship-oriented and reliability-focused, emphasizing "speed, reliability, ease-of-use" and long-term partnership with private-equity sponsors and borrowers rather than short-hold trading of credit.
Notable Investments
- DOCS Dermatology Group — US$205 million unitranche financing (announced March 2026) alongside Antares Capital and New Mountain to refinance and upsize the SkyKnight Capital–backed dermatology platform after six 2025 practice acquisitions.
- Recochem — Participated (with CapVest and H.I.G.) in the acquisition/financing of Recochem, a global manufacturer of aftermarket transportation and household fluids (announced ~November 2023).
- Arrowhead Engineered Products — Provided capital alongside Genstar Capital for Arrowhead, a distributor of aftermarket replacement parts; Penfund made an additional investment (~March 2022).
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.